Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a point of concern for investors.

In a bid to rework the controversial relationship between drugmakers and patient charities, Regeneron Pharmaceuticals has announced a new program in which it will match up to $200 million in ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.

On June 17, 2025, Regeneron Pharmaceuticals, Inc. (“Regeneron”) filed another complaint against Amgen Inc. (“Amgen”) under the BPCIA, alleging that ...

Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...

Regeneron launches a $200 million matching donation program for Good Days’ Retinal Disease Fund to enhance patient access to medicines.

Through this program, Regeneron has committed to matching donations at a one-to-one rate, up to a total of $200 million, for the remainder of the 2025 calendar year.

By Colin Kellaher Regeneron Pharmaceuticals has won Food and Drug Administration accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

Regeneron will announce Q2 2025 results on August 1, 2025, and host a conference call at 8:30 AM ET. Regeneron Pharmaceuticals, Inc. announced that it will disclose its second quarter 2025 ...

It may be a year later than originally planned, but Regeneron Pharmaceuticals Inc. is set to commercialize Lynozyfic (linvoseltamab) in the U.S. following FDA approval for use in adults with relapsed ...